Coinhibitory Pathways in Immunotherapy for Cancer.

By Susanne H. Baumeister, G. Freeman, G. Dranoff, Arlene H. Sharpe. Annual Review of Immunology, 2016

862 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/ebf5810b8a9e5bc8248de9777d376dfec6905638

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. É. Vivier
2. G. Lee
3. Erika L. Pearce

In Oncology

1. G. Lee
2. Erika L. Pearce

Citations in the corpus

• Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells (2018, background): “Immuno-oncology has revolutionized cancer treatment (Okazaki and Honjo, 2007; Okazaki et al., 2013; Baumeister et al., 2016; Schumacher and Schreiber, 2015; Sharma and Allison, 2015a, 2015b).”
• The Balance of Th17 versus Treg Cells in Autoimmunity (2018, background): “Although we still do not know how these pathways play Treg-specific roles, we do know that blocking these co-inhibitory pathways using anti-PD1 and anti-CTLA-4 antibodies promotes anti-cancer activity; such blocking antibodies are used widely for cancer treatment [51].”
• Unraveling the Complex Interplay Between T Cell Metabolism and Function (2018, background): “Persistent antigen exposure causes the functional impairment of Te cells, a phenotype associated with diminished glucose metabolism (82, 83).”